Altman Advisors Inc. Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Altman Advisors Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 121.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 35,260 shares of the company’s stock after purchasing an additional 19,309 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.0% of Altman Advisors Inc.’s holdings, making the stock its 29th biggest position. Altman Advisors Inc.’s holdings in Novo Nordisk A/S were worth $2,343,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL increased its holdings in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $29,000. Transce3nd LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $33,000. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $27,000. Finally, Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $67.32 on Wednesday. The company has a market cap of $300.59 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.33 and a beta of 0.64. The firm’s fifty day moving average is $70.37 and its 200 day moving average is $74.73. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $142.23.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the topic of several recent analyst reports. Guggenheim downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating for the company. Finally, BMO Capital Markets restated a “market perform” rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.